Evidence map›Paper›PMID 30228951›Full record

ReviewOncoimmunology

Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy.

Robert E Jordan, Xuejun Fan, Georgina Salazar, Ningyan Zhang, Zhiqiang An

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Robert E JordanThe Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Health Science Center, University of Texas Medical School at Houston, Texas, USA.
Xuejun FanThe Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Health Science Center, University of Texas Medical School at Houston, Texas, USA.
Georgina SalazarThe Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Health Science Center, University of Texas Medical School at Houston, Texas, USA.
Ningyan ZhangThe Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Health Science Center, University of Texas Medical School at Houston, Texas, USA.
Zhiqiang AnThe Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Health Science Center, University of Texas Medical School at Houston, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The host immune system adopts multiple mechanisms involving antibodies to confront cancer cells. Accordingly, anti-tumor mAbs have become mainstays in cancer treatment. However, neither host immunity nor mAb therapies appear capable of controlling tumor growth in all cases. Structural instability of IgG was overlooked as a factor contributing to immunosuppression in the tumor microenvironment. Recently, physiological proteinases were identified that disable IgG immune effector functions. Evidence shows that these proteinases cause localized IgG impairment by selective cleavage of a single IgG peptide bond in the hinge-region. The recognition of IgG cleavage in the tumor microenvironment provides alternatives for tumor immunotherapy.

Indexed as

antibody immunityanti-hinge antibodycancer immune evasionsingle proteinolytic cleavage of the IgG hingetumor microenvironment

Identifiers

PMID30228951
PMCPMC6140550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.